Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00080483 · ClinicalTrials.gov registry record · Phase 2

Testosterone and Growth Hormone for Bone Loss in Men

A Phase 2 study of Hypogonadism and Growth Hormone Deficiency, sponsored by University of Pennsylvania.

Completed
Registry status
Phase 2
Development phase
35
Enrollment target
1
Study location

NCT00080483 is a Phase 2 study of Hypogonadism and Growth Hormone Deficiency that has completed, run by University of Pennsylvania. The registered enrollment target is 35 participants, below the 119-participant average among 21 other Hypogonadism trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00080483, a Phase 2 study of Hypogonadism and Growth Hormone Deficiency, has completed, sponsored by University of Pennsylvania.

COMPLETED
Registry status
Phase 2
Development phase
35 participants
Enrollment target
1
Study location

Study Summary

Deficiency of testosterone, growth hormone, or both hormones can result in osteoporosis. If either hormone is replaced, the condition of the bones improves. The purpose of this study is to determine if dual hormone treatment for men deficient in testosterone and growth hormone improves bone structure more than testosterone treatment alone.

Interventions

  • DRUG Testosterone plus somatropin
  • DRUG testosterone

Study Locations (1)

Pennsylvania

  • Hospital of the University of Pennsylvania - Philadelphia

Trial Details

FieldValue
Enrollment Target 35 participants
Start Date 2004-03
Est. Completion 2010-09
Phase Phase 2

Sponsor

University of Pennsylvania

1,423 total trials

What the Registry Record Tells You About NCT00080483

The ClinicalTrials.gov registry entry for NCT00080483 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 119-participant average among 21 other Hypogonadism trials with a reported enrollment target (71% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Hypogonadism appearing as the primary indexed condition, and to 2 interventions - of which Testosterone plus somatropin is the first listed.

NCT00080483 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT00080483 about?

NCT00080483 is a clinical study titled "Testosterone and Growth Hormone for Bone Loss in Men". Deficiency of testosterone, growth hormone, or both hormones can result in osteoporosis. If either hormone is replaced, the condition of the bones improves. The purpose of this study is to determine if dual hormone treatment for men deficient in testosterone and growth hormone improves bone structur...

What is the current status of trial NCT00080483?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2004-03. Estimated completion is 2010-09.

What conditions does trial NCT00080483 study?

This clinical trial studies the following conditions: Hypogonadism, Growth Hormone Deficiency, Hypopituitarism.

What interventions are being tested in trial NCT00080483?

The interventions under investigation include: Testosterone plus somatropin (DRUG), testosterone (DRUG).

Who is sponsoring clinical trial NCT00080483?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00080483 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hypogonadism

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.